AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints
Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 29, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck ’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021
Results from Phase 3 trial, STRIDE-3, to be presented at World... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
EDINBURGH, Scotland, Nov. 27, 2023. TC BioPharm (Holdings) PLC ( " TC BioPharm " or the " Company " ) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
FDA Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection
TAIPEI, Nov. 21, 2023. Senhwa Biosciences, Inc., a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that U.S. Food and Drug Administration has approved its Phase... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Viriom's Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials
SAN DIEGO, Nov. 20, 2023. Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
Leuven, BELGIUM, Boston, MA, US– November 20, 2023– 7:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
OCEANIC-AF Study Investigating Asundexian Stopped Early Due to Lack of Efficacy
Berlin, November 19, 2023– OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer
ORINDA, Calif., Nov. 17, 2023. CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) with the recommended Phase 2 dose (RP2D) of ivaltinostat (ClinicalTrials.gov ID NCT05249101).
The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma
First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA®... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase 2 Spring Trial Of LHP588, Treatment For P. Gingivalis-positive Alzheimer's Disease Proceeds
SAN FRANCISCO, Nov. 16, 2023. Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer ' s and other diseases of aging, today announced clearance by the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
Astellas Announces Data from ASPIRO Study for AT132 (resamirigene bilparvovec) in X-linked Myotubular Myopathy Published in The Lancet Neurology
TOKYO, Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, " Astellas " ) today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients
YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. ( " RemeGen " or " the Company " ), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
